Market overview

Market Overview — October 28–29, 2026

Risk tone: Markets are in a cautiously risk-on mode, but with signs of rotation rather than broad-based conviction. The VIX fell 3.48% on October 28, settling near 17.5, below the commonly watched 20 stress threshold, down from a spike that moved from about 15 to 20 a couple weeks earlier on investor fears about AI spending and financing. That easing in volatility is consistent with the measured levels: SPY and DIA posted modest session gains (+0.34%/+0.27%) while the equal-weight RSP was roughly flat, and the breadth read (RSP 1m +2.73% vs SPY) shows the rally broadening beyond mega-caps rather than narrowing.

Macro driver — the Fed: The dominant catalyst was Wednesday's FOMC decision. The Federal Reserve kept the fed funds target range at 3.75%-4.00% on Wednesday, 28 October 2026, in a 10-2 vote, with Governor Lisa Cook and Cleveland Fed President Beth Hammack both wanting a 25bp hike. Stocks edged up as the Fed held rates steady and refrained from offering a clear signal on whether it will hike in December, and traders are pricing about an 85% chance of a Fed rate hike on December 9. Notably, policymakers had raised rates by a quarter point at the September meeting — the first hike since 2023 — and the dissents underscored continuing concern about inflation even as Chair Kevin Warsh said the central bank remained focused on "price stability" despite the pause and that the employment picture has been "quite positive."

Standout moves: Mega-cap tech was the earnings focal point into the close — stocks closed higher after the Fed held rates, then Fortinet fell 26.2% and Alphabet 10.8% after hours after results, while Microsoft and Chipotle rose — which helps explain why QQQ's intraday session gain (+0.60%) didn't translate into 1-month leadership (QQQ is lagging SPY by 2.73% over the past month per the regime read, consistent with recent AI-capex jitters and post-earnings air pockets in names like Alphabet). Biotech was the clear standout sector: XBI's outsized +1.72% session move on Oct 28 tracks with continued momentum in the space — XBI closed October 27 at $154.84 (+2.90%), while the Nasdaq Biotechnology Index closed at 7,150.77 (+1.87%) — though the 1-month and 3-month regime figures above show that excess risk appetite is actually being pared back relative to the broader market, suggesting the sector's gains are more idiosyncratic (M&A, trial data) than a sign of broad speculative risk-taking.

Bottom line: The tape reflects a market digesting a "hawkish hold" from the Fed — rates steady but a live December hike risk — with volatility compressed, participation broadening beyond the largest tech names (Dow and equal-weight S&P outperforming the Nasdaq-100 on a one-month basis), and mega-cap earnings (Microsoft/Alphabet) acting as the next swing factor heading into month-end.